Table 3.
Changes in urinary excretion of 8-iso-PGF2α at day 28
| Placebo (n = 20) | Empagliflozin 10 mg (n = 20) | Empagliflozin 25 mg (n = 19) | |
|---|---|---|---|
| Fasting state, pg/ml | |||
| Baseline | 197.8 (27.0) | 194.6 (29.4) | 146.5 (18.5) |
| Change from baseline at day 28 | 40.6 (22.6) | −48.1 (23.3) | −33.5 (23.7) |
| Difference vs placebo (95% CI) | −88.6 (−154.6, −22.7) | −74.0 (−139.8, −8.2) | |
| p-value | 0.010 | 0.028 | |
| In 24 hours after drug administration, pg/ml | |||
| Baseline | 115.5 (11.0) | 138.3 (20.6) | 148.6 (21.7) |
| Change from baseline at day 28 | −3.7 (10.3) | −28.4 (10.4) | −46.8 (10.6) |
| Difference vs placebo (95% CI) | −24.7 (−54.5, 5.2) | −43.1 (−72.9, −13.3) | |
| p-value | 0.103 | 0.006 |
Baseline data are mean (standard error [SE]), change from baseline data are adjusted mean (SE) based on analysis of covariance (ANCOVA) in the full analysis set.